Vor Biopharma VOR Payment Of Issuance Costs Related To Underwritten Public Offering And Private Placements
Payment Of Issuance Costs Related To Underwritten Public Offering And Private Placements at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept vor:PaymentOfIssuanceCostsRelatedToUnderwrittenPublicOfferingAndPrivatePlacements.
The official record: Vor Biopharma’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vor Biopharma's payment of issuance costs related to underwritten public offering and private placements.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vor Biopharma's payment of issuance costs related to underwritten public offering and private placements?
- Vor Biopharma (VOR) reported payment of issuance costs related to underwritten public offering and private placements of $331.25K in Q4 2025.
- How has Vor Biopharma's payment of issuance costs related to underwritten public offering and private placements changed year-over-year?
- Vor Biopharma's payment of issuance costs related to underwritten public offering and private placements decreased by 43.0% year-over-year, from $581.25K to $331.25K.
- What is the long-term trend for Vor Biopharma's payment of issuance costs related to underwritten public offering and private placements?
- Over 2 years (2023 to 2025), Vor Biopharma's payment of issuance costs related to underwritten public offering and private placements has grown at a 35.9% compound annual growth rate (CAGR), from $717K to $1.33M.
- What does payment of issuance costs related to underwritten public offering and private placements mean?
- This represents the direct costs incurred, such as legal, accounting, and registration fees, associated with raising capital through public or private offerings. Monitoring these costs helps evaluate the efficiency of the company's capital-raising activities.